Targeting Fibronectin May Reduce Alzheimer's Risk for APOE4 Carriers

Preclinical research identifies a pathway to repair blood-brain barrier damage in Alzheimer's disease models, with potential implications for a specific genetic subgroup.

Columbia University neuroscientist Çağhan Kızıl and his lab published findings in Nature Aging on September 18, 2026, showing fibronectin accumulation disrupts blood-brain barrier integrity in Alzheimer's disease models. Their work used human cells, three-dimensional blood-vessel models, APOE4 mice, and zebrafish to demonstrate that reducing fibronectin levels reversed blood-brain barrier leakage in zebrafish exposed to amyloid-beta. The research also identified a rare genetic variant (FN1 loss-of-function) associated with a 71% reduction in Alzheimer's disease risk specifically for APOE4 carriers without adverse effects.

This mechanism suggests that targeting fibronectin at brain blood vessels could restore barrier integrity by blocking its suppression of protective growth signals. The potential impact lies in reducing long-term healthcare costs and improving quality of life for APOE4 carriers—a genetic subgroup representing a significant portion of Alzheimer's patients—by addressing the root cause of vascular leakage. However, interventions have not yet shown cognitive benefits in animals or humans.

The next critical step is validating these findings in larger human cohorts through clinical trials. Current limitations include the preclinical nature of the models, the need to avoid disrupting fibronectin’s essential roles in wound healing and vascular maintenance, and the fact that the 71% risk reduction applies only to APOE4 carriers. This research moves abundance toward a more targeted approach to Alzheimer's care but requires rigorous human testing before broader healthcare applications.

Source: ScienceAlert